{"CONCEPT_ID":[19054702,19009705,44507865,19106100,19020068,937368,1314273,537647,1304565,19012585,19137385,1325608,1353011,792929,45774639,1593031,40244464,779271],"CONCEPT_PATH":["VARIOUS||DIAGNOSTIC RADIOPHARMACEUTICALS||Iodine (125I) compounds||fibrinogen||fibrinogen","ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS||IMMUNOSTIMULANTS||Colony stimulating factors||lenograstim||lenograstim","NA||NA||NA||prothrombin||prothrombin","BLOOD AND BLOOD FORMING ORGANS||ANTIHEMORRHAGICS||Blood coagulation factors||factor XIII||factor XIII","RESPIRATORY SYSTEM||OTHER RESPIRATORY SYSTEM PRODUCTS||Other respiratory system products||nitric oxide||nitric oxide","ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS||IMMUNOSUPPRESSANTS||Tumor necrosis factor alpha (TNF-a) inhibitors||infliximab||infliximab","ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS||ANTINEOPLASTIC AGENTS||Monoclonal antibodies||rituximab||rituximab","ANTIINFECTIVES FOR SYSTEMIC USE||IMMUNE SERA AND IMMUNOGLOBULINS||Specific immunoglobulins||palivizumab||palivizumab","VARIOUS||ALL OTHER THERAPEUTIC PRODUCTS||Detoxifying agents for antineoplastic treatment||rasburicase||rasburicase","ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS||ANTINEOPLASTIC AGENTS||Other antineoplastic agents||asparaginase||asparaginase","ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS||ANTINEOPLASTIC AGENTS||Ethylene imines||thiotepa||thiotepa","ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS||IMMUNOSTIMULANTS||Colony stimulating factors||pegfilgrastim||pegfilgrastim","VARIOUS||ALL OTHER THERAPEUTIC PRODUCTS||Detoxifying agents for antineoplastic treatment||dexrazoxane||dexrazoxane","ANTIINFECTIVES FOR SYSTEMIC USE||ANTIVIRALS FOR SYSTEMIC USE||Other antivirals||letermovir||letermovir","ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS||IMMUNOSUPPRESSANTS||Selective immunosuppressants||vedolizumab||vedolizumab","MUSCULO-SKELETAL SYSTEM||OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM||Other drugs for disorders of the musculo-skeletal system||nusinersen||nusinersen","ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS||ANTINEOPLASTIC AGENTS||Janus-associated kinase (JAK) inhibitors||ruxolitinib||ruxolitinib","NA||NA||NA||vipivotide tetraxetan||vipivotide tetraxetan"],"NUM_PERSONS":[244,239,168,160,143,125,121,105,74,71,59,58,57,52,50,50,49,36],"PERCENT_PERSONS":[0.00244,0.00239,0.00168,0.0016,0.00143,0.00125,0.00121,0.00105,0.00074,0.00071,0.00059,0.00058,0.00057,0.00052,0.0005,0.0005,0.00049,0.00036],"RECORDS_PER_PERSON":[1.0082,1,1,1.00625,1,1,1.00826,1,1,1,1,1.01724,1,1,1,1,1,1]}
